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Purpose: This study is to directly compare surgical outcomes between conventional
nipple-sparing mastectomy (CNSM) and robot-assisted nipple-sparing mastectomy
(RNSM).
Materials and Method: For this case–control study, 369 cases of 333 patients who
underwent CNSM or RNSM with immediate reconstruction between November 2016 and
January 2019 at Severance Hospital in Seoul, Republic of Korea were reviewed. Patients
with stage IV breast cancer (n = 1), receiving neoadjuvant chemotherapy (n = 43), or
subjected to previous operations (n = 14) or radiotherapy on the breasts were excluded.
The main outcomes were comparing rates of post-operative complications, of high-grade
post-operative complications as defined by the Clavien-Dindo classification, and nipple
necrosis between the CNSM and the RNSM groups.
Results: A total of 311 cases, including 270 CNSMs and 41 RNSMs, were analyzed. The
rates of post-operative nipple necrosis (p = 0.026, 2.4 vs. 15.2%) and of high-grade post-
operative complications (p = 0.031, 34.8 vs. 17.1%) in the RNSM group were significantly
lower than those in the CNSM group.
Conclusion: RNSM was associated with lower rates of high-grade post-operative
complications and nipple necrosis than CNSM for patients with small breast volumes
and less ptotic breasts.
Keywords: breast neoplasms, robotic mastectomy, nipple-sparing mastectomy, minimal invasive surgery,
nipple necrosisINTRODUCTION
Nipple-sparing mastectomy (NSM) has been widely applied to women with early breast cancer or
BRCA 1/2 mutations (1–4). Because NSM preserves the nipple areolar complex (NAC) and
overlying skin, NSM results in better cosmetic outcomes coupled with oncologic safety for those
patients, compared to conventional total mastectomy or skin-sparing mastectomy (4–9).January 2021 | Volume 10 | Article 5943881
Lee et al. Nipple Necrosis of Robotic MastectomyNipple necrosis is one of the most common complications
after NSM (1, 2, 10, 11). Previous studies reported 0–48% of
nipple ischemia or nipple necrosis in patients undergoing NSM
with immediate reconstruction (1, 12). In order to reduce nipple
ischemia or necrosis, various techniques have been proposed in
previous studies (12, 13). Rusby et al. showed that placement of
incisions far from the NAC and reconstruction using a tissue
expander (T/E) reduced the risk of NAC necrosis (12). Petit et al.
reported that leaving a layer 5 mm of glandular tissue beneath
the NAC for preserving its blood supply is beneficial to reduce
NAC necrosis (13). However, there is no universal solution for
reducing nipple necrosis after NSM.
Many surgeons have tried to develop various incisions in
NSM to deliver better cosmetic outcomes (14–16). Robot-
assisted nipple-sparing mastectomy (RNSM) is a procedure
that uses robotic systems through axillary or lateral incisions,
which results in no scars in the overlying skin. A previous study
reported that RNSM presented with low rates of nipple necrosis
(17–19). However, there has been, to our knowledge, a lack of
comparisons between RNSM and conventional NSM (CNSM) in
terms of nipple necrosis rates.
This study aimed to evaluate nipple necrosis rates between
RNSMandCNSM.Additionally, grades and rates of complications
after the two procedures were analyzed and compared.MATERIALS AND METHODS
Patients
A total of 333 patients in the present study had undergone CNSM
or RNSM between November 2016 and January 2019 at Severance
Hospital, Seoul, Korea. Their medical records and post-operative
photographs taken by plastic surgeons were retrospectively
reviewed. The photographs were taken on 1, 2, 3, 5, 7, and 9 days
after the operation of autologous reconstruction routinely. After a
prosthetic reconstruction, post-operative photographs were takenFrontiers in Oncology | www.frontiersin.org 2on 1, 2, 4, 6, and 8 days after the operation. In an outpatient
department, plastic surgeons take the photographs as needed.
Exclusion criteria were the presence of stage IV disease (n = 1),
treatment with neoadjuvant chemotherapy (n = 43), and previous
operation or radiation history (n = 14). This resulted in a total of
311 cases, 270 caseswithCNSMand41caseswithRNSM, from275
patients being enrolled in the study (Figure 1). Among them, 36
patients underwent either bilateral CNSMorRNSM.There was no
male patient in this study because patients who underwent
immediate reconstruction after mastectomy were collected.
Clinicopathologic features, including age, BMI, breast
volume, ptosis, disease entities, TNM stage, estrogen and
progesterone receptor, human epidermal growth factor
receptor (HER) 2 status, Ki 67 levels, adjuvant therapies,
reconstruction methods, duration of hospital stays, and
operation times were analyzed. Post-operative complications
through 1–28 months, including nipple ischemia or necrosis,
skin ischemia or necrosis, infection, bleeding, lymphedema,
limitation of shoulder movement, contracture, seroma, wound
dehiscence, and arterial thrombus, were also analyzed. Nipple
ischemia in this study was defined as a clinical ischemic color
change in the NAC. Nipple necrosis was defined as full-thickness
necrosis of the NAC requiring surgical intervention (1). Grades
of post-operative complications were analyzed according to the
Clavien-Dindo classification (20).
Procedures
CNSM was performed using various methods by three breast
surgeons (Figure 2). Immediate reconstruction, including tissue
expander (T/E), direct-to-implant (DTI), Latissimus dorsi (LD)
flap, and transverse rectus abdominis musculocutaneous
(TRAM) flap, was performed according to surgeons’ and
patients’ preferences by three plastic surgeons. A deep inferior
epigastric perforator flap was included in the TRAM flap. RNSM
was performed via single axillary or lateral incision by a breast
surgeon. Gas or gasless technique in robotic mastectomy wasFIGURE 1 | Schematic diagram of the study population.January 2021 | Volume 10 | Article 594388
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(17–19, 21). The detailed techniques were described in previous
studies (17–19, 21). T/E insertion or DTI was applied for
immediate reconstruction in those patients (19, 21).
Pathologic Evaluations
Estrogen receptor (ER), progesterone receptor (PR), HER2 status,
and Ki 67 levels were analyzed by immunohistochemistry (IHC), as
described in previous studies (22). In brief, positivity for ER and PR
was defined as ≥1% nuclear staining in IHC. HER2 2+ in IHC and
amplification in fluorescence in situ hybridization/silver in situ
hybridization or 3+ in IHC were considered overexpression
according to ASCO/CAP guidelines (23). The cut-off values for Ki
67 staining for low and high proliferative index were < and ≥14%
staining in IHC, respectively (24). TNM stage was classified
according to anatomic stage as in the AJCC 8th edition. Nipple
margins were reviewed from both intra-operative frozen and post-
operative permanent pathologic evaluations.
Adjuvant Therapies
Chemotherapy, endocrine therapy, and radiation therapy were
delivered according to standard guidelines or physicians’
preferences (25). Patients with HER2-positive disease and tumor
sizes ≥1 cm routinely received adjuvant trastuzumab therapy.
Statistics
A learning curve of RNSM for total operation time was analyzed
using three-day moving average curves (3D-MAC), and the
cumulative sum (CUSUM) technique. 3D-MAC is used to
analyze the existence of a learning curve (26). This simple
moving average is defined as the mean value of previous 3
days data points (27). The CUSUM technique is a statistical
method to assess the learning curve quantitatively and toFrontiers in Oncology | www.frontiersin.org 3calculate the sequential difference between the individual and
the mean value of all data (28). The CUSUM is estimated by
CUSUM =oni=1(xi − m), where xi is an individual operation
time, and µ is the mean value of overall operation time (29).
Categorical variables were analyzed using either Chi-square test
or Fisher’s exact test, if indicated. Continuous variables were
analyzed using either Student’s t test or Mann–Whitney test, if
indicated. All tests were two-sided. Multivariate analysis was
performed using binary regression with backward elimination
(conditional) to evaluate risk factors related with high-grade
complications (Clavien-Dindo classification ≥grade III). A p-value
less than 0.05 was considered to be statistically significant. All
statistical analyses were performed using the SPSS software,
version 25 (SPSS Inc., Chicago, IL). We did not use a statistical
matching technique due to the limited sample size. Missing values
were imputed as null values.
Ethics
This study was approved by the institutional review board at
Severance Hospital (4–2019–0510).RESULTS
The clinicopathologic features of the enrolled patients are shown in
Table 1. The mean age of patients was 45.93 ± 8.34 (data not
shown). There were no differences in clinicopathologic features
between the CNSM and RNSM groups, except in breast volumes,
laterality, and ptosis. Ptotic breasts were more frequent and breast
volumes were larger in the CNSM group. Others subgroup in BRCA
mutation included three cases with PALB2 mutations (Table 1).
Post-operative outcomes, including length of hospital stay and
operation times are shown in Table 2. The length of hospital stay inA B
FIGURE 2 | Various types of incisions in conventional nipple-sparing mastectomy and robot-assisted nipple-sparing mastectomy. (A) Types of incision in
conventional nipple-sparing mastectomy: 1) Lower-periareolar incision with/without extension, 2) Radial incision, 3) Curvilinear incision, 4) Upper-periareolar incision
with/without extension, 5) Elliptical incision, 6) Inframammary fold incision; (B) Type of incision in robot-assisted nipple-sparing mastectomy: 7) Lateral incision.January 2021 | Volume 10 | Article 594388
Lee et al. Nipple Necrosis of Robotic MastectomyTABLE 1 | Clinicopathologic characteristics of the study population.
CNSM RNSM p-valueb
(n = 270) (n = 41)
Age (years) 46 ± 8.0 44 ± 10.0 0.075c
BMI (kg/m2) 22.5 ± 3.1 21.7 ± 2.3 0.065c
Breast volume (g) 428 ± 222.0 326 ± 143.0 0.002c
Laterality Unilateral 216 (80.0) 23 (56.1) 0.001
Bilateral 54 (20) 18 (43.9)
Ptosis Normal 136 (50.4) 32 (78.0) 0.004
Mild 56 (20.7) 8 (19.5)
Moderate 36 (13.3) 0 (0.0)
Severe 38 (14.1) 1 (2.4)
Pseudoptosis 2 (0.7) 0 (0.0)
BRCA1 mutation No 89 (81.7) 16 (94.1) 0.913
Yes 11 (10.1) 1 (5.9)
VOUS 6 (5.5) 0 (0.0)
Others 3 (2.8) 0 (0.0)
BRCA2 mutation No 89 (81.7) 10 (58.8) 0.050
Yes 12 (11.0) 6 (35.5)
VOUS 5 (4.6) 1 (5.9)
Others 3 (2.8) 0 (0.0)
Diagnosis Benign 5 (1.9) 4 (9.8) 0.069
DCIS 63 (23.3) 9 (22.0)
Invasive carcinoma 185 (68.5) 25 (61.0)
BRCA mutation carrier 17 (6.3) 3 (7.3)
ERa Negative 49 (19.8) 3 (8.8) 0.123
Positive 199 (80.2) 31 (91.2)
PRa Negative 64 (25.8) 8 (23.5) 0.775
Positive 184 (74.2) 26 (76.5)
HER2a Negative 174 (76.3) 21 (63.6) 0.117
Positive 54 (23.7) 12 (36.4)
Ki 67a Low (<14%) 108 (44.3) 13 (38.2) 0.632
High (≥14%) 136 (55.7) 21 (61.8)
Histologic gradea Grade I 59 (23.8) 5 (14.7) 0.445
Grade II 144 (58.1) 21 (61.8)
Grade III 45 (18.1) 8 (23.5)
Ta Tis 67 (27.0) 11 (32.4) 0.615
T1 144 (58.1) 20 (58.8)
T2 37 (14.9) 3 (8.8)
Na N0 210 (86.1) 30 (88.2) 0.653
N1 29 (11.9) 3 (8.8)
N2 4 (1.6) 1 (2.9)
N3 1 (0.4) 0 (0.0)
TNM stagea 0 68 (27.4) 8 (23.5) 0.766
I 126 (50.8) 20 (58.8)
II 48 (19.4) 5 (14.7)
III 6 (2.4) 1 (2.9)
Adjuvant chemotherapya No 167 (67.3) 23 (67.6) 0.971
Yes 81 (32.7) 11 (32.4)
Radiotherapya No 220 (88.7) 30 (88.2) 0.935
Yes 28 (11.3) 4 (11.8)
Hormone therapya No 58 (23.4) 5 (14.7) 0.254
Yes 190 (76.6) 29 (85.3)
Target therapya No 231 (93.1) 29 (85.3) 0.161
Yes 17 (6.9) 5 (14.7)
Recurrencea No 246 (99.2) 41 (100.0) > 0.999
Yes 2 (0.8) 0 (0.0)Frontiers in Oncology | www.frontiersin.org 4 January 2021 | Volume 10 | ArticValues are represented as mean ± SD or number (percentage).
BMI, body mass index; CNSM, conventional nipple-sparing mastectomy; DCIS, ductal carcinoma in situ, ER, estrogen receptor; HER, human epidermal growth factor receptor;
PR, progesterone receptor; RNSM, robot-assisted nipple-sparing mastectomy; VOUS, variants of unknown significance.
a29 cases of benign disease or BRCA mutation carriers were not included (n = 282).
bChi-square test or Fisher’s exact test.
cStudent’s t test or Mann–Whitney test.le 594388
Lee et al. Nipple Necrosis of Robotic Mastectomythe RNSM group was greater than in the CNSM group (p < 0.001,
14 ± 4 vs. 12 ± 3 days), and the same held for total operation time
(p < 0.001, 308.9 ± 75.5 vs. 303.9 ± 195.9 min). Mastectomy time
was longer in the RNSM group than the CNSM group (p < 0.001,
181.5 ± 44.7 vs. 104.5 ± 40.5 min), Reconstruction time was longer
in the CNSM group than the RNSM group (p = 0.019, 196.8 ± 182.5
vs. 140.5 ± 52.5 min).
T/E was the most common method for immediate
reconstruction in both groups (Table 2). TRAM is the second
most common method for immediate reconstruction in the
CNSM group. Approximately half of the patients underwent
DTI after RNSM.
Incision types are described in Table 2. Periareolar with
extension was the most common incision in the CNSM group,
followed by IMF, radial, elliptical, and curvilinear incision. Lateral or
axillary incision was only used in the RNSM group. Incision types
between the two groups were significantly different (p < 0.001).
There was no significant difference of margin status between two
groups. The CNSM group included one nipple and two superficial
margins of tumor involvement. The RNSM group had one
superficial margin involvement of tumor (Table 2). One patient
who underwent RNSM showed false negative in subareolar mass in
frozen section. Because the final pathology revealed invasive ductal
carcinoma in the mass, NAC was sacrificed.
Figure 3 shows grades of post-operative complications and
nipple necrosis rates between the two groups. Post-operativeFrontiers in Oncology | www.frontiersin.org 5complication rates were not different between the CNSM and
RNSM groups (p = 0.176, 58.5 vs. 46.3%). There was no
significant difference in implant loss and infection rates
between the groups (for implant loss, p = 0.347, 0.7% for the
CNSM group vs. 2.4% for the RNSM group, for infection, p =
0.101, 2.2% for the CNSM group vs. 7.3% for the RNSM group,
data not shown). Post-operative complications requiring surgical
intervention, such as wound revision, drain re-insertion, fat graft
injection for volume defects, and implant removal were more
common in the CNSM group (p = 0.031, grade ≥III, 34.8% vs.
17.1%). Nipple necrosis rate was significantly lower in the RNSM
group than in the CNSM group (p = 0.026, 2.4 vs. 15.2%).
Multivariate analysis was conducted to evaluate risk factors
related to high-grade complications. The rate of high-grade
complications (grade ≥III) was statistically associated with the
methods of the mastectomy and the operation time (p = 0.046
and p < 0.001) (Table 3).DISCUSSION
Our study demonstrated the advantage of RNSM compared to
the CNSM in terms of nipple necrosis rate. Previous studies
suggested that certain incision types are significantly associated
with nipple necrosis because the viability of the NAC is mainly
maintained by blood supply from dermal layers (4, 30). AnotherTABLE 2 | Surgical methods and post-operative outcomes.
CNSM RNSM p-valueb
(n = 270) (n = 41)
Hospital stay (days) 12 ± 3 14 ± 4 0.001c
Total operation time (min) 303.9 ± 195.9 308.9 ± 75.5 <0.001c
Mastectomy time (min) 104.5 ± 40.5 181.5 ± 44.7 <0.001c
Console time (min) – 64 ± 40 –
Reconstruction time (min) 196.8 ± 182.5 140.5 ± 52.5 0.019c
Operation site Left 139 (51.5) 19 (46.3) 0.616
Right 131 (48.5) 22 (53.7)
Reconstruction types T/E 190 (70.4) 21 (51.2) <0.001
DTI 5 (1.9) 20 (48.8)
TRAM 73 (27.0) 0 (0.0)
LD 2 (0.7) 0 (0.0)
Incision types IMF 51 (18.9) 0 (0.0) <0.001
Radial 32 (11.9) 0 (0.0)
Upper-periareolar with extension 120 (44.4) 0 (0.0)
Lower-periareolar with extension 52 (19.3) 0 (0.0)
Curvilinear 3 (1.1) 0 (0.0)
Elliptical 12 (4.4) 0 (0.0)
Lateral or axillary 0 (0.0) 41 (100.0)
SLNBa No 20 (7.7) 2 (5.9) >0.99
Yes 239 (92.3) 32 (94.1)
ALNDa No 224 (86.5) 31 (91.2) 0.592
Yes 35 (13.5) 3 (8.8)
Margin statusa No 240 (96.8) 32 (94.1) 0.404
Yes 3 (1.2) 1 (2.9)January 2021 | Volume 10 | ArticValues are represented as mean ± SD or number (percentage).
ALND, axillary lymph node dissection; CNSM, conventional nipple-sparing mastectomy; DTI, direct-to-implant; IMF, inframammary fold; LD, latissimus dorsi flap; RNSM, robot-assisted
nipple-sparing mastectomy; SLNB, sentinel lymph node biopsy; T/E, tissue expander; TRAM, transverse rectus abdominis musculocutaneous flap.
a29 cases of benign disease or BRCA mutation carriers were not included (n = 282).
bChi-square test or Fisher’s exact test.
cStudent’s t test or Mann–Whitney test.le 594388
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FIGURE 3 | Comparison of post-operative complications between conventional nipple-sparing mastectomy and robot-assisted nipple sparing mastectomy. (A) Rate
of complications, (B) Grade of complications, (C) Rate of nipple necrosis.Frontiers in Oncology | www.frontiersin.org January 2021 | Volume 10 | Article 5943886
Lee et al. Nipple Necrosis of Robotic Mastectomystudy presented that a transaxillary incision could be the incision
of choice for NSM with valid, oncological safe, and excellent
cosmetic results in breast cancer patients or BRCA mutation
carriers (31). For this reason, small axillary or lateral incisions in
RNSM may have beneficial effects on the integrity of overlying
skin and the NAC.
The rate of complications was not statistically different between
the RNSM and the CNSM groups. Grades of post-operative
complications were significantly different between the two groups.
Compared to CNSM, RNSM showed lower rates of high-grade
complications in the univariate and multivariate analysis. This
different rate of high-grade complication may be due to different
types of immediate reconstruction procedures. A previous study in
our institution reported that reconstruction with TRAM free flap,
LD flap with implant, and DTI presented with more post-operative
NAC necrosis than reconstruction with a T/E (1). Similarly,
another study reported that higher grades of post-operative
complications occurred more commonly in patients with
autologous reconstructions compared to those with implant-based
reconstructions (32). In the present study, approximately one
third (27.7%) of patients in the CNSM group underwentFrontiers in Oncology | www.frontiersin.org 7autologous reconstructions, and this may influence the higher
grade of post-operative complications in this group. Therefore, it
is important to consider types of reconstruction procedure as a
stratification factor when conducting randomized clinical trials in
the future.
In the present study, RNSM was mainly performed on patients
with small- to medium-sized breasts without ptosis. This is
concordant with previous studies (19). Toesca et al. mainly
enrolled women with small- to medium-sized breasts with low
grade ptosis in their randomized clinical trial (19, 33). This may be
due to the fact that implant-based reconstruction is suitable for
small- to medium-sized breasts with low grade ptosis. Implant-
based reconstructions constituted the major reconstruction method
after RNSM because LD or TRAM flap requires additional incisions
compared to implant-based reconstruction. Autologous
reconstruction after RNSM remained as a technical challenge of
robotic surgery.
Operation times for mastectomy were longer in the RNSM
group than in the CNSM group in this study. Robotic surgery,
including thyroidectomy, colectomy, and gastrectomy, presented
with longer operation times than conventional surgery (34–36).TABLE 3 | Multivariate analysis for risk factors related with high-grade complications.
Clavien-Dindo Classification ≥Grade III
OR (95% CI) p-value
Age (≤50 vs. >50) 0.751 (0.381–1.480) 0.408
Breast volume (≤310 g vs. >310 g) 1.638 (0.862–3.111) 0.132
Ptosis (Normal vs. Ptotic) 0.904 (0.489–1.673) 0.748
Operation time (min) 1.005 (1.004–1.007) <0.001
Operation method (CNSM vs. RNSM) 0.406 (0.167–0.986) 0.046January 2021 | Volume 10 |CNSM, conventional nipple-sparing mastectomy; RNSM, robot-assisted nipple-sparing mastectomy.FIGURE 4 | Learning curve of robot-assisted nipple-sparing mastectomy. CUSUM, cumulative sum technique; OP, operation; RNSM, robot-assisted nipple-sparing
mastectomy; 3D MAC, 3-day moving average curve.Article 594388
Lee et al. Nipple Necrosis of Robotic MastectomyThis is due to the development of the working space, the robot
docking, and surgeon’s experience (37). This is also the case with
RNSM. Mean mastectomy time in the RNSM group was 181.5 min,
and it was longer than mastectomy time in the CNSM group
(95.5 min). However, as RNSM is a new technique, there was a
learning period in the initial cases in this study. Even though
operation times during RNSM decreased over time (Figure 4), a
significant learning curve associated with a new technique such as
RNSM may account for longer operation times compared to
conventional procedures. Despite increased duration of
mastectomy, console time in RNSM was approximately 1 hour
(Table 2). Further studies regarding learning curves are necessary
for comparisons of the two groups in terms of duration
of operation.
Hospital stays were longer in the RNSM group than in the
CNSM group. However, with a difference of only two days, there
was no significant impact on clinical outcomes because there are
differences in hospital stays according to surgeons’ preferences
(data not shown).
There are several limitations to this study. The retrospective
design of this study may have led to selection bias. Propensity
matching would be an alternative method to reduce the
limitations of a retrospective study. Also, the numeric disparity
between the RNSM and CNSM groups was another limitation.
Patient satisfaction and cosmetic outcomes, which may be one of
the main advantages of RNSM, were not measured. A lack of
detailed information on reconstructive techniques, such as
subpectoral or prepectoral techniques, was another limitation
of the study. Oncologic outcomes, such as loco-regional
recurrence-free survival, disease-free survival, and overall
survival, are important end-points in the treatment of patients
with breast cancer. Prospective studies with longer follow-ups are
needed to overcome these limitations. However, to the best of
our knowledge, this is the largest study to evaluate differences in
terms of grades of complications and rates of nipple necrosis
between RNSM and CNSM. Moreover, the results of the current
study support the feasibility and safety of robotic mastectomy
as a treatment option for women with breast cancer or
BRCA mutations.Frontiers in Oncology | www.frontiersin.org 8CONCLUSION
This study indicated that RNSM may have some advantages in
terms of lower nipple necrosis and grade of post-operative
complications. Further multicenter studies evaluating the
clinical implications of RNSM should be conducted in the future.DATA AVAILABILITY STATEMENT
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